JP7610537B2 - シナプス変性症の処置における使用のためのメチルチオニニウム - Google Patents

シナプス変性症の処置における使用のためのメチルチオニニウム Download PDF

Info

Publication number
JP7610537B2
JP7610537B2 JP2021577316A JP2021577316A JP7610537B2 JP 7610537 B2 JP7610537 B2 JP 7610537B2 JP 2021577316 A JP2021577316 A JP 2021577316A JP 2021577316 A JP2021577316 A JP 2021577316A JP 7610537 B2 JP7610537 B2 JP 7610537B2
Authority
JP
Japan
Prior art keywords
therapeutic composition
acid
compound
synaptic
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021577316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538286A (ja
JP2022538286A5 (enExample
Inventor
ロバート ハリントン，チャールズ
リーデル，ゲルノット
ミシェル ウィスチク，クロード
Original Assignee
ウィスタ ラボラトリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィスタ ラボラトリーズ リミテッド filed Critical ウィスタ ラボラトリーズ リミテッド
Publication of JP2022538286A publication Critical patent/JP2022538286A/ja
Publication of JP2022538286A5 publication Critical patent/JP2022538286A5/ja
Application granted granted Critical
Publication of JP7610537B2 publication Critical patent/JP7610537B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021577316A 2019-07-02 2020-06-29 シナプス変性症の処置における使用のためのメチルチオニニウム Active JP7610537B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1909506.6 2019-07-02
GBGB1909506.6A GB201909506D0 (en) 2019-07-02 2019-07-02 Synaptopathies
PCT/EP2020/068306 WO2021001326A1 (en) 2019-07-02 2020-06-29 Methylthioninium for use in the treatment of synaptopathies

Publications (3)

Publication Number Publication Date
JP2022538286A JP2022538286A (ja) 2022-09-01
JP2022538286A5 JP2022538286A5 (enExample) 2023-07-07
JP7610537B2 true JP7610537B2 (ja) 2025-01-08

Family

ID=67540130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577316A Active JP7610537B2 (ja) 2019-07-02 2020-06-29 シナプス変性症の処置における使用のためのメチルチオニニウム

Country Status (12)

Country Link
US (1) US20220370470A1 (enExample)
EP (1) EP3993805A1 (enExample)
JP (1) JP7610537B2 (enExample)
KR (1) KR20220029711A (enExample)
CN (1) CN114080224A (enExample)
AU (1) AU2020300792B2 (enExample)
BR (1) BR112021025383A2 (enExample)
CA (1) CA3143787A1 (enExample)
GB (1) GB201909506D0 (enExample)
IL (1) IL289371A (enExample)
MX (1) MX2021015288A (enExample)
WO (1) WO2021001326A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148145A (en) 2006-07-11 2013-03-15 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
WO2021211640A1 (en) * 2020-04-14 2021-10-21 University Of Florida Research Foundation, Incorporated Enhanced effects of gene-immunotherapy and immunosuppressants in multiple sclerosis
US12410394B2 (en) 2023-01-06 2025-09-09 Athergen, Inc. Composition comprising nicotinamide mononucleotide and leucomethylene blue

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018019823A1 (en) 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020040032A1 (en) 2000-07-07 2002-04-04 Glasky Michelle S. Methods for stimulation of synthesis of synaptophysin in the central nervous system
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
AU2008265045B2 (en) 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
CA2701075C (en) 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
JP6756661B2 (ja) 2017-04-28 2020-09-16 日立オートモティブシステムズ株式会社 車両電子制御装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018019823A1 (en) 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Francesco PANZA et al.，"Tau-Centric Targets and Drugsin Clinical Development for the Treatment of Alzheimer’sDisease"，BioMed Research International，2016年，Vol. 2016，p.1-15，DOI: 10.1155/2016/3245935
Gernot RIEDEL et al.，"Mechanisms ofAnticholinesterase Interference with Tau Aggregation Inhibitor Activity in aTau-Transgenic Mouse Model"，Current Alzheimer Research，2020年05月18日，Vol. 17, No. 3，p.285-296，DOI: 10.2174/1567205017666200224120926
Santosh JADHAV et al.，"A walk through tau therapeuticstrategies"，Acta Neuropathologica Communications，2019年02月15日，Vol. 7, No. 22，DOI:10.1186/s40478-019-0664-z

Also Published As

Publication number Publication date
KR20220029711A (ko) 2022-03-08
CN114080224A (zh) 2022-02-22
US20220370470A1 (en) 2022-11-24
MX2021015288A (es) 2022-01-18
CA3143787A1 (en) 2021-01-07
AU2020300792B2 (en) 2026-03-19
AU2020300792A1 (en) 2022-02-24
JP2022538286A (ja) 2022-09-01
GB201909506D0 (en) 2019-08-14
BR112021025383A2 (pt) 2022-02-01
IL289371A (en) 2022-02-01
WO2021001326A1 (en) 2021-01-07
EP3993805A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
JP7610537B2 (ja) シナプス変性症の処置における使用のためのメチルチオニニウム
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
US20230165877A1 (en) Administration and dosage of diaminophenothiazines
JP2021193119A (ja) Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
JP7757446B2 (ja) リソソーム蓄積障害に関する医薬組成物及び使用
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
SG188144A1 (en) Alpha 7 nicotinic agonists and antipsychotics
US20220288048A1 (en) Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
US20100099762A1 (en) Combination therapy
CA2807510A1 (en) Inhibitors of erk for developmental disorders of neuronal connectivity
AU2015343060A1 (en) Methods of treating Huntington's Disease using cysteamine compositions
RU2835868C2 (ru) Метилтиониний, предназначенный для лечения синаптопатий
US20230031369A1 (en) Therapeutic interactions of leucomethylthioninium
JP2022518733A (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
WO2022159086A1 (en) Improved treatment for globoid cell leukodsytrophy or krabbe disease
JP2018528953A (ja) リソソーム障害及び中枢神経系の変性障害の治療及び予防のための（３ｒ，４ｒ，５ｓ）−５−（ジフルオロメチル）ピペリジン−３，４−ジオールを含むレジメン
RU2853626C2 (ru) Фармацевтические композиции и применения против лизосомных болезней накопления
JP2025518248A (ja) メチルチオニニウム（ｍｔ）含有化合物を利用した神経変性障害の処置
HK40109096B (en) Optimised dosage of diaminophenothiazines in populations
HK40106579B (en) Administration and dosage of diaminophenothiazines
HK40002533A (en) Administration and dosage of diaminophenothiazines
HK40002533B (en) Administration and dosage of diaminophenothiazines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241220

R150 Certificate of patent or registration of utility model

Ref document number: 7610537

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150